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Since the occurrence of West Nile virus (WNV) infec-
tion in humans in 2008 in Italy, concerns have been 
raised about the potential risks associated with solid 
organ transplantation (SOT). A nationwide retrospec-
tive survey showed that 1.2% of SOT donors in 2009 
were WNV-seropositive and demonstrated that human 
WNV infection is distributed throughout several Italian 
regions. Transmission of WNV or other arboviruses 
through SOT is a possibility and risk assessment 
should be carried out before SOT to avoid infection 
through transplantation.
Background
In 1998, when the first cases of equine West Nile virus 
(WNV) infection in Italy were detected in Tuscany, no 
human cases were reported [1]. WNV re-emerged in 
Italy in 2008, and viral circulation was identified among 
different vectors and different animal species, includ-
ing horses and wild birds [2]. The first cases of human 
WNV neuroinvasive infections in Italy were identified in 
September 2008 in the Emilia-Romagna region [3]. 
In the summer of 2009, additional human cases were 
reported in the same and in other neighbouring Italian 
regions. In one of the most affected areas in the prov-
ince of Ferrara, a WNV seroprevalence of 0.68% was 
observed in healthy blood donors, raising concerns 
about the potential risks of WNV transmission by blood 
transfusion and organ transplantation [4,5]. 
In 2009, as a precautionary measure, the National 
Transplant Centre issued guidance that potential dona-
tions from all donors of  solid organs, tissues and cells 
from the Bologna, Ferrara, Modena and Reggio-Emilia 
provinces who were screened by nucleic acid amplifi-
cation tests (NAAT) for the presence of WNV viraemia, 
and tested positive, had to be rejected. Donors from 
other regions who had spent at least one overnight 
stay in the above-listed provinces during the 28 days 
before donation should not be considered eligible for 
donation [6]. 
Two days before screening of donors was implemented, 
in Bologna, Emilia-Romagna province, transmission 
of WNV infection through liver transplantation was 
detected by NAAT before clinical symptoms appeared 
in the recipient. The transmission of WNV was man-
aged, post-transplant, by administration of hyperim-
mune serum and viraemia-guided adjustment of the 
immunosuppressive drug regimen, accompanied by 
supportive care [7].  The patient recovered from the 
transplantation and did not develop symptoms of WNV 
infection or sequelae. Before this case, all reported 
SOT donor-derived WNV infections were identified 
retrospectively in symptomatic transplanted patients 
with severe outcomes in the United States (US) [8]. 
This post-transplant detection of WNV infection in SOT 
recipients demonstrates that the absence of a univer-
sal screening policy in the immediate pre-transplant 
period makes it almost impossible to accurately quan-
tify the transmission rate and the subsequent clinical 
impact of WNV transmission to SOT recipients. In the 
US, a recent serosurvey carried out among SOT recipi-
ents suggested that asymptomatic WNV infection may 
be common in areas of WNV activity and that the severe 
clinical presentations of WNV infections are equally 
frequent in both immunocompromised and immuno-
competent subjects [9].
On the basis of this evidence, re-defining the risks for 
WNV transmission by organ, tissue and cell transplan-
tation was identified by the National Transplant Centre 
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as a necessary safety measure before the start of the 
next WNV season, from late spring to early autumn. 
The Italian Transplant Network considered this to be 
a priority in order to establish the factual basis for 
implementing future strategies for preventing WNV 
transmission.  
A nationwide retrospective survey of WNV seropreva-
lence was therefore undertaken in all SOT donors 
recruited by the National Transplant Centre during 
2009.
Methods
Serum samples from the Italian SOT donors in 2009 
stored in the biorepository facilities of the Italian 
Transplant Network, were analysed by the two refer-
ence laboratories identified by the National Transplant 
Centre for assessment of WNV infection: the Laboratory 
of Virology at the National Institute for Infectious 
Diseases ’L. Spallanzani‘ in Rome and the Regional 
Reference Centre for Microbiological Emergencies of 
the Microbiology Unit, St Orsola–Malpighi University 
Hospital, in Bologna. 
The presence of WNV-specific IgG and IgM was inves-
tigated using a two-step approach: first, a screening 
test was performed using a commercial enzyme-linked 
immunosorbent assay (ELISA) method (Euroimmun, 
AG, Lübeck, Germany); all samples that were positive 
for either IgG or IgM were then confirmed by an immun-
ofluorescent antibody assay (IFA, Euroimmun). Second, 
the IgG-positive sera were further evaluated by ELISA 
to measure the IgG avidity, using the method of Fox 
et al. [10]. All the IgG- and IgM-positive samples identi-
fied in the previous steps were further characterised 
by microneutralisation assay (MNTA) against WNV 
as previously described [11], and to rule out possible 
cross-reactions of the test, serum samples were also 
tested by MNTA against Usutu virus. All IgM-positive 
sera samples were retrospectively tested by NAAT 
using Procleix-WNV assay performed on the TIGRIS 
system, Novartis (for donors from Emilia Romagna) or 
Artus Real Art WNV LC RT RCRt kit,  QIAGEN  (for donors 
from Piedmont and Tuscany) in order to evaluate the 
presence of WNV viraemia. During the screening activ-
ity for WNV in 2009 no WNV-positive donor was identi-
fied before SOT.
Results
A total of 1,248 serum samples from SOT donors in 2009 
were analysed, accounting for 98.1% of SOT donors 
recruited during that year. Table 1 lists the number of 
SOT donors evaluated in this study, by region of resi-
dence. WNV-specific antibodies were detected in 15 
samples from individual donors at the time of organ 
donation, thus giving an overall positivity rate of 1.2%. 
Data from MNTA indicate that seven of 15 samples had 
Table 1
Region of residence of solid organ donors tested for West Nile virus, Italy, 2009 (n=15)
Region Number of donors tested Number of donors positive WNVa
Abruzzo-Molise 12 0
Basilicata 11 1
Calabria 12 0
Campania 74 0
Emilia Romagna 120 4
Friuli-Venezia Giulia 45 1
Lazio 103 1
Liguria 33 0
Lombardy 226 0
Marche 51 0
Piedmont-Aosta Valley 120 2
Bolzano-Bozen independent provincial administration 10 0
Trento independent provincial administration 17 0
Apulia 44 0
Sardinia 24 0
Sicily 59 0
Tuscany 167 6
Umbria 11 0
Veneto 109 0
Total 1,248 15 
WNV: West Nile virus
 a IgG - and/or IgM-positive, by serological screening (see Table 2).
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neutralisation activity against WNV. However, eight 
samples did not show appreciable neutralisation titre 
against WNV. Among these, two samples were reverse 
transcription-polymerase chain reaction (RT-PCR) posi-
tive and two other samples probably showed neutrali-
sation activity against the related Usutu virus (Table 2).
The inability to confirm by MNTA all the samples test-
ing positive by ELISA and IFA might be due to the 
cross-reactivity to closely related flaviviruses or might 
be consistent with the notion that the neutralising 
response to WNV in humans is variable and that only 
a subset of infected individuals generate antibodies 
against high-neutralising epitopes [12]. Furthermore, 
from a technical point of view, maturation state of WNV 
particles used in the MNTA might have been impor-
tant for determining whether antibodies in a given 
serum samples were judged WNV-specific by MNTA , as 
already reported by Nelson et al. [13].
The highest number of WNV-seropositive donors were 
from the regions of Emilia-Romagna and Tuscany (Table 
1 and Figure). 
Table 2 shows the place of residence, demographic 
information and laboratory results obtained for these 
15 patients. 
Two donors (from Piedmont and Emilia-Romagna) were 
identified as IgG- and IgM-positive. One donor, from 
Tuscany, was positive only for IgM.  All these three 
IgM-positive samples were also positive for viral RNA, 
showing quite a low viral load (equivalent to a genome 
copy number of ≤3 log copies/ml).  We speculate that 
such a low level of viral concentration in blood is likely 
to pose a limited risk of viral transmission through 
SOT. Four IgG-positive specimens showed an antibody 
avidity of 80% to 90% suggesting that exposure to 
WNV probably occurred more than six months before 
the organ donation; another four IgG-positive samples 
(all from donors who donated organs after June 2009) 
showed an antibody avidity lower than 40 %, suggest-
ing that the infection was probably acquired within six 
months before the organ donation, a time frame con-
sistent with WNV exposure during the 2009 mosquito 
season (June to October). 
In addition, recipients of a solid organ from donors who 
were shown to have been positive for WNV genome 
or to have had IgM-specific antibodies at the time of 
organ donation were also included in this study. Two 
recipients from the Piedmont IgM-positive donor (one 
kidney recipient and one liver recipient) did not show 
any seroconversion to WNV. The remaining recipient 
(who received a kidney) was not available for testing. 
All three recipients are well and have never shown 
signs consistent with WNV infection. The IgM-positive 
donor from Tuscany did not in the end donate organs 
for reasons not related to WNV infection.
Discussion and conclusions
The occurrence of an antibody response in some donors 
from the Piedmont, Friuli-Venezia Giulia, Marche and 
Basilicata regions is rather unexpected and shows 
evidence of WNV infection in humans in several Italian 
regions. However, it is possible that WNV activity has 
hitherto been underestimated in some regions, due to 
an insufficient veterinarian and entomological surveil-
lance system, which may have generated inconsistent 
data.  Evidence from the present study – i.e. the low IgG 
avidity index, the presence of an IgM-specific response 
and/or WNV RNA in blood samples – is consistent with 
the notion that recrudescence of WNV activity in Italy 
occurred in the last two years, following the report 
of the first human cases of neuroinvasive disease 
[3-5]. These findings highlights the need for an accu-
rate nationwide approach to risk assessment related 
to transplantation, in order to implement appropriate 
prevention strategies and limit the potential burden of 
severe neurological complications in the immunocom-
promised recipients.  During the 2009 season, only 
one case of WNV transmission by SOT was observed 
in the Emilia-Romagna region [7]. No additional cases 
of WNV transmission from infected donors were docu-
mented retrospectively in our study, suggesting that 
the transmission of WNV to recipients of SOT from 
viraemic donors does not always occur. Furthermore, 
Figure
Distribution of solid organ donors shown to be positive 
for West Nile virusa, Italy, 2009 (n=15)
a Shown to have West Nile virus-specific antibodies (IgG and/
or IgM) by enzyme-linked immunosorbent assay (ELISA) and  
immunofluorescent antibody assay (IFA).
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the positivity in MNTA against Usutu virus in two sam-
ples additionally confirms that this virus has to be 
added to the list of those that can be transmitted to 
humans [14,15] and its possible transmission through 
SOT deserves particular attention.
These results indicate that, due to the well-known cir-
culation of WNV in many different areas in Italy, trans-
mission of WNV or other arboviruses through SOT is 
possible, and that the risk assessment process related 
to transplantation is a challenging issue that requires a 
systematic approach [7].
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Table 2
Detailed information of solid organ donors who tested positive by serological screening for West Nile virus
Region Sampling date, 2009 Cause of death
Age at 
death 
(years)
Place of 
residence
(province)
Possible place of exposurea 
(if different from 
place of residence)
WNV- specific 
antibody titres
IgG 
avidity 
(%)b
MNTA 
titre 
against 
WNVdIgG IgM
Basilicata 22 Sep Stroke 64 Matera Lake Garda  ≥1:160 <1:10 89 1:40
Lazio 7 Jul Stroke 67 Rome – 1:80 <1:10 31 1:40
Tuscany 3 Jan Cranial trauma 57 Lucca – 1:80 <1:10 NA <1:10
Tuscany 26 Mar Brain haemorrhage 67 Versilia (Lucca) – 1:40 <1:10 NA <1:10
Tuscany 15 Jul Stroke 87 Florence – <1:10 1:10c NA <1:10
Tuscany 25 Aug Brain haemorrhage 74 Siena – 1:80 <1:10 11 1:20
Tuscany 20 Oct Brain haemorrhage 40 Prato – ≥1:160 <1:10 43 <1:10
Tuscany 13 Nov Cranial trauma 85 Livorno – ≥1:160 <1:10 68 1:80
Piedmont 28 Jul Asphyxia/hypoxia 57 Mottalciata (Biella) – 1:80 <1:10 73 <1:10
e
Piedmont 21 Oct Post-anoxic coma 63 Chieri (Turin) – 1:160 1:40
c 13 <1:10
Emilia 
Romagna 23 Feb Heart failure 71 Modena – 1:400 <1:10 88 1:80
Emilia 
Romagna 14 May Brain haemorrhage 56
Traversetolo 
(Parma) – 1:200 <1:10 52 <1:10
f
Emilia 
Romagna 1 Sep Brain haemorrhage 78 Naples Reggio Emilia >1:1600 1:80
c 25 1:160
Marche 1 Aug Brain haemorrhage 48 Rimini – 1:400 <1:10 84 1:20
Friuli-
Venezia 
Giulia
24 Jul Cranial gunshot wound 63 Gorizia – 1:1600 <1:10 88 <1:10
MNTA: microneutralisation assay; NA: not applicable, due to low or negative IgG enzyme-linked immunosorbent assay (ELISA) optical density 
values; WNV: West Nile virus.
a For the donors whose place of residence was not in the WNV activity area identified in 2008 and 2009, the possible place of WNV exposure 
was provisionally assigned by a retrospective investigation based on consultation of medical records or on direct information received by 
the donors’ relatives. The dashes (–) in this column indicate that no history of travel in WNV-endemic areas other than those identified in 
Italy was recorded in the 12 months before donation. 
b <40% : less than 6 months after infection; >60% : 6 months or more after infection, according to [10].
c Positive for WNV by reverse transcription-polymerase chain reaction (RT-PCR).
d Samples yielding a neutralisation titre ≥ 1:20 were scored as positive. 
e MNTA titre against Usutu virus 1:40.
f MNTA titre against Usutu virus 1:80.
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